Established in 1958, Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Formulations and Active Pharmaceutical Ingredients (APIs). Qilu currently has 13 subsidiaries, 11 manufacturing sites and over 30,000 employees worldwide. It ranks among Top 10 in Chinese pharmaceutical industry by sales revenue in 2020. Dedicated to offering high-quality & trustworthy medicines to the world and improving people‘s well-being, Qilu is vigorously exporting its products to over 80 countries and regions.
Products Marketed in China
Pharmaceutical Companies In China
We continue to strengthen our R & D capabilities to build a robust and diversified portfolio for a sustainable business. Qilu always maintains an innovative development strategy and is achieving its organic growth leveraging its robust pool of 3,000+ scientists spread across 5 R & D centers based in the US (Seattle, Boston, San Francisco) and China (Shanghai, Jinan). To date, Qilu has launched 300+ products with 50+ products “First-to-Launch” in China. The company has also fostered a robust pipeline including 200+ generic products, 30+ biosimilars and 80+ innovative products.
Qilu always commits itself to offering high-quality & trustworthy medicines to the world and improving people’s well-being. It is the first Chinese company to obtain both USFDA and EDQM approval for sterile APIs. Its Finished Formulations and APIs have been approved by USFDA, EMA, TGA, MHRA, PMDA, etc.
Qilu maintains a robust and sustainable growth in global markets while consistently foraying into new geographies to further fortify its position globally. With a well-established domestic and overseas sales network, you may find Qilu’s footprints across the world.